MAZE THERAPEUTICS, INC. Increase (Decrease) in Receivables
MAZE THERAPEUTICS, INC. (MAZE) reported Increase (Decrease) in Receivables of $20.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2026-05-12
- MAZE THERAPEUTICS, INC. increase (decrease) in receivables for the quarter ending 2026-03-31 was $20.00M.
| Period end | Increase (Decrease) in Receivables 3 month |
|---|---|
| 2026-03-31 | $20.00M 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |